B cell MALT lymphoma diagnosed by labial minor salivary gland biopsy in patients screened for Sjogren's syndrome
van Mello, N.M.; Pillemer, S.R.; Tak, P.P.; Sankar, V.

Published in:
Annals of the Rheumatic Diseases

Citation for published version (APA):
B cell MALT lymphoma diagnosed by labial minor salivary gland biopsy in patients screened for Sjögren’s syndrome

N M Van Mello, S R Pillemer, P P Tak and V Sankar

Ann Rheum Dis 2005;64:471-473
doi:10.1136/ard.2004.022707

Updated information and services can be found at:
http://ard.bmj.com/cgi/content/full/64/3/471

References
This article cites 10 articles, 3 of which can be accessed free at:
http://ard.bmj.com/cgi/content/full/64/3/471#BIBL

2 online articles that cite this article can be accessed at:
http://ard.bmj.com/cgi/content/full/64/3/471#otherarticles

Rapid responses
You can respond to this article at:
http://ard.bmj.com/cgi/eletter-submit/64/3/471

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections
Connective tissue disease (208 articles)

Notes

To order reprints of this article go to:
http://www.bmjournals.com/cgi/reprintform

To subscribe to Annals of the Rheumatic Diseases go to:
http://www.bmjournals.com/subscriptions/
B cell MALT lymphoma diagnosed by labial minor salivary gland biopsy in patients screened for Sjögren’s syndrome

N M Van Mello, S R Pillemer, P P Tak, V Sankar

Case report: Three patients presented to the Sjögren’s syndrome (SS) Clinic at the National Institute of Dental and Craniofacial Research for screening. The records of patients with SS and a diagnosis of lymphoma were examined to determine whether the diagnosis was made in any of the cases as a result of labial salivary gland (LSG) biopsies. All patients had typical features of primary SS according to the American-European Consensus Group criteria. B cell mucosa associated lymphoid tissue (MALT) lymphoma was diagnosed based upon the LSG biopsy.

Conclusion: This report underlines the advantages of performing LSG biopsies as a routine part of screening for SS, and shows that it may in some instances lead to early diagnosis of MALT lymphomas in patients who show no signs of pre-existing lymphoma.

Sjögren’s syndrome (SS) is an autoimmune exocrinopathy characterised by decreased lachrymal and salivary gland function, resulting in keratoconjunctivitis sicca and dry mouth.1 Lymphocytic infiltration in these glands is a major feature of SS. These infiltrates consist of mononuclear cells, which penetrate the glandular epithelial tissue and are called benign lymphoepithelial lesions.2 One of the criteria for classification of SS includes the presence of ≥1 foci of 50 or more lymphocytes (a focus) within a 4 mm² field3 in a labial salivary gland (LSG) biopsy specimen.

SS generally follows a rather indolent course, but development of malignant lymphoma may occur.4 It has been estimated that patients with SS have an up to 44 times increased risk of developing lymphoma5 compared with the general population. Lymphoma has been reported in 4.3% of patients with SS.6 In most cases, this is a low grade B cell lymphoma of the mucosa associated lymphoid tissue (MALT) type. Thus far, lymphoma has been diagnosed in patients with SS with atypical or persistent major salivary gland swelling. biopsy or resection of the affected gland histopathologically confirmed the diagnosis of B cell MALT lymphoma.7,8

In this article, we report on three patients who were screened for SS. Each was found to have a MALT lymphoma upon labial minor salivary gland biopsy. None of the patients appeared to have pre-existing lymphoma, fever, night sweats, or persistent major salivary gland swelling at the time of evaluation.

CASE REPORTS

Case 1
Patient 1, a 53 year old white woman, presented with a 2.5 year history of oral and ocular dryness, which began precipitously with an episode of sun exposure and photo-sensitive rash. This was accompanied by generalised inflammation and swelling of the extremities. Subsequently, she had an unintentional weight loss of 9 kg and was referred to an oncologist, who found no apparent cause for this loss of weight. Her review of symptoms was significant for Raynaud’s phenomenon, vasculitis, shortness of breath on climbing stairs, and swelling of the legs, feet, and ankles.

Upon physical examination, the patient had multiple non-blanching purpuric lesions on the lower limbs. The conjunctivae were injected, and there was no salivary gland enlargement or lymphadenopathy. Upon examination of the blood samples, the alkaline phosphatase (192 U/l), glutamic pyruvic transaminase (53 U/l), glutamic oxalacetic transaminase (48 U/l), total protein (84 g/l), IgG (17.00 g/l), IgM (8.04 g/l), C reactive protein (10.5 mg/l), and erythrocyte sedimentation rate (ESR; 72 mm/1st h) were raised, while C4 (<0.1 g/l) levels were decreased. Additionally, the antinuclear antibodies (ANA), anti-SSA, and antiribonucleoprotein antibody tests were positive. She had keratoconjunctivitis sicca by both Van Bijsterveld score on ocular dye staining and the Schirmer I test. A major salivary lymphoma biopsy disclosed extranodal marginal zone B cell lymphoma of the MALT type, expressing monoclonal k light chain and CD43 coexpression. The infiltrate was focally positive for CD20; the neoplastic cells were CD3 negative.

The patient was then referred for bone marrow aspirate and biopsy, which showed localisation of non-Hodgkin’s lymphoma. A positron emission tomography scan showed a focal area of intense tracer uptake in the right chest area that appeared to be near the pleural pericardial surface on the right anteriorly, which could represent lymphoma.

Case 2
Patient 2, a 51 year old Middle Eastern woman, presented with oral dryness complaints of 1 year’s duration and 3 years of ocular dryness. The patient had a history of intermittent swelling of the parotid glands, approximately two episodes a year, for the past 3–4 years. She had a history of smoking with chronic hoarseness. There was no history of unintentional weight loss or vasculitis.

Blood tests showed raised levels of total protein (92 g/l), amylase (167 U/l), IgG (28.40 g/l), IgA (4.74 g/l), IgM (2.41 g/l), rheumatoid factor (473 IU/ml) and a raised ESR (70 mm/1st h), while C4 levels (0.10 g/l) and white blood cell count (2.54×10⁹/l) were decreased. Additionally, the ANA, anti-SSA, and anti-SSB antibody tests were positive. The patient had keratoconjunctivitis sicca, as shown by both the Schirmer I test and Van Bijsterveld score on ocular dye staining. The salivary flow was decreased and met SS flow requirements according to the American-European criteria. The minor salivary gland biopsy revealed an atypical lymphoid infiltrate, expressing excess k light chains and suspicious of involvement of the extranodal marginal zone B

Abbreviations: ANA, antinuclear antibodies; ESR, erythrocyte sedimentation rate; LSG, labial salivary gland; MALT, mucosa associated lymphoid tissue; SS, Sjögren’s syndrome
cell lymphoma of the MALT type. The patient was then referred to oncology for staging of her lymphoma.

Case 3

Patient 3, a 55 year old woman, presented with a 25 year history of SS. She complained of dryness of the mouth, skin, nose, and vagina, as well as a gritty and sandy feeling in her eyes. She had had an episode of vasculitis on her upper arms and a history of fatigue. She had experienced frequent, intermittent swelling of the parotid glands for the past 20 years, which had been well controlled with 5 mg prednisone daily. Her history was significant for hypothyroidism, shingles, and oral and genital herpes. Six years before the current evaluation she had non-Hodgkin’s lymphoma of the right groin, which went into complete remission after chemotherapy.

Upon examination of the blood the ANA, rheumatoid factor, and anti-SSA antibody titres were positive, and the ESR (81 mm/1st h) was raised. Keratoconjunctivitis sicca was confirmed by an increased Van Bijsterveld score on ocular dye staining as well as by the Schirmer I test and she met salivary flow requirements according to the American-European criteria. A minor salivary gland biopsy showed a marginal zone B cell lymphoma of the MALT type, expressing monoclonal λ light chains. She was then referred to her physician for staging of the MALT lymphoma and treatment was started with Leukeran (4 mg daily) and her prednisone was increased to 20 mg/day.

DISCUSSION

Described here are three middle-aged women, who presented to the clinic with typical features of primary Sjögren’s syndrome on first evaluation. Each patient had subjective complaints and objective evidence of ocular and oral dryness according to the American-European Consensus Group criteria and were all ANA and anti-extractable nuclear antigen positive (anti-SSA, anti-SSB, and/or anti-RNP antibodies). Patients 1 and 2 both had low C4 levels, which have been associated with an increased risk for development of lymphoma in patients with SS. Ten of the three patients had no pre-existing lymphoma, in contrast with the third patient who had a history of non-Hodgkin’s lymphoma that appeared to be in remission. All three patients were diagnosed with a marginal zone B cell MALT lymphoma with monoclonal light chain expression upon LSG biopsy.

MALT is normally found in Peyer’s patches in the ileum of the lower gastrointestinal tract, where it has an important role in the normal humoral immune response. Mononuclear cell lymphocytic infiltrates in the exocrine glands can develop into marginal zone B cell lesions or acquired MALT. These infiltrates are still benign and functional. However, patients with SS have an increased risk of developing monoclonal B cell MALT lymphoma. It has been suggested that prolonged autoimmune inflammation as in SS or persistent antigenic stimulation due to for instance to H pylori and human herpes virus infection may play a part in the development of lymphoma.^{11, 12}

It has been recently shown that the level of circulating BAFF (BLyS, TALL-1, THANK, zTNF4) correlates with the level of autoantibodies in human SS. BAFF is a B cell activating factor, which regulates B cell differentiation and proliferation. It is considered to have a pathogenetic role in activating specific autoreactive B cells and modulating the level of production of autoantibodies which are diagnostic criteria of SS.^{13} Now shown is that a spectrum of B cell tumour cells express BAFF and BAFF receptors. The research indicates that these B cells deregulate an otherwise physiologic autocrine survival pathway and evade apoptosis.^{14} Under high B cell activity, marginal zone B cells may form germinal centres in the salivary glands of some patients with SS, which could give rise to oligoclonal populations of B cells, possibly resulting in MALT lymphoma.^{15} Conceivably, diminution of inflammation through immunomodulatory treatment might play a role in the prevention and treatment of lymphoma in SS, similar to the effects of elimination of antigenic stimulation by eradication of H pylori, leading to regression of the MALT lymphoma.

LSG biopsies, aside from being a part of the SS diagnostic criteria, can offer clues to the presence of a lymphoma. Biopsies should be carefully evaluated for lymphoma, especially when the mononuclear cells have a uniform appearance. Histologically, they can show atypical plasmacytoid cells and Dutcher bodies. Upon suspicion, the specimen should be immunohistochemically stained to determine the presence of polyclonal plasmacytosis for confirmation of the final diagnosis. Further research may clarify the potential role of measuring BAFF levels in these biopsy specimens as a marker for increased risk of lymphoma in patients with SS.

The present report describes three patients who presented as typical patients with SS, but who were diagnosed with MALT lymphoma only on their labial minor salivary gland biopsy. These findings underline the need for degree of awareness of the possibility of lymphoma in patients with features of SS. By performing LSG biopsies routinely as a part of screening, lymphomas which might otherwise escape detection can be found.

Authors’ affiliations

N M Van Mello, S R Pillemer, V Sankar, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, DHHS, Bethesda, MD 20892-1190, USA

N M Van Mello, P P Tak, Division of Clinical Immunology and Rheumatology, Academic Medical Centre, NL-1105, AZ Amsterdam, The Netherlands

Correspondence to: Professor P P Tak, Division of Clinical Immunology and Rheumatology, Academic Medical Centre/University of Amsterdam, F-4 218, PO Box 22700, 1100 DE Amsterdam, The Netherlands; P.P.Tak@amc.uva.nl

Accepted 12 August 2004

REFERENCES


www.annrheumdis.com
Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking authors:
- Child health: nocturnal enuresis
- Eye disorders: bacterial conjunctivitis
- Male health: prostate cancer (metastatic)
- Women’s health: pre-menstrual syndrome; pyelonephritis in non-pregnant women

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:
- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with Clinical Evidence editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every six months using any new, sound evidence that becomes available.
  The Clinical Evidence in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.
- To expand the topic to include a new question about once every 12–18 months.

If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicalevidence.com or contact Klara Brunnhuber (kbrunnhuber@bmjgroup.com).